Arthur McGivern is a partner in Goodwin's Technology & Life Sciences group and a member of its Life Sciences and Capital Markets practices. Mr. McGivern works on a wide variety of public and private securities offerings, mergers and acquisitions, royalty-based financings and other complex transactions in the life sciences sector. He also represents public and private companies in their ongoing corporate matters, including SEC compliance and corporate governance, as well as investment banks, hedge funds and other private investment funds in public securities-related matters.

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Mr. McGivern’s recent representations include:
  • Intellia Therapeutics, a leading genome editing company, in its (i) $15 million Series A financing, (ii) foundational license agreement with Caribou Biosciences pursuant to which Intellia has the right to therapeutic applications of CRISPR/Cas9 technology, (iii) exclusive collaboration and license agreement with Novartis, (iv) exclusive collaboration and license agreement with Regeneron, (v) $70 million Series B financing, (vi) $112 million initial public offering and concurrent $55 million private placements and (vii) follow-on public offerings, raising over $225 million
  • Repligen Corporation, a NASDAQ-listed bioprocessing company, in multiple equity offerings, raising nearly $350 million, multiple convertible note offerings raising more than $400 million and in its acquisitions of (i) Novozymes Biopharma’s bioprocessing business, (ii) Refine Technology’s Alternating Tangential Flow (“ATF”) System, (iii) Atoll GmbH, (iv) TangenX, (v) Spectrum Life Sciences and (vi) C Technologies
  • Royalty Pharma, a leading investor in pre-approval royalties, in its purchases of royalties in transactions valued at more than $10 billion, including (i) its $3.3 billion acquisition of the Cystic Fibrosis Foundation’s royalties on Vertex Pharmaceuticals’ cystic fibrosis treatments, the largest pharmaceutical royalty purchase ever completed, (ii) its $1.14 billion acquisition of UCLA’s royalties on Xtandi, (iii) synthetic royalty financing totaling more than $2 billion with BioHaven, Immunomedics, Sanofi and other confidential counterparties, (iv) its acquisition of royalties on worldwide sales of Tysabri® from Perrigo Company plc for $2.2 billion plus potential milestone payments up to $650 million and (v) its $827 million acquisition of Ligand Pharmaceuticals’ royalties on sales of Promacta
  • Foundation Medicine, a cancer diagnostics company, in (i) a $55 million private financing, (ii) its subsequent $120 million initial public offering on the NASDAQ Stock Market, (iii) its collaboration agreement and equity transaction with Roche, total value in excess of $1 billion, and (iv) its complete acquisition by Roche, which valued Foundation Medicine at $2.4 billion
  • Esperion Therapeutics, a Michigan-based pharmaceutical company developing a treatment for elevated levels of LDL cholesterol, in (i) a $17 million private financing, (ii) its subsequent $80 million initial public offering on the NASDAQ Stock Market, (iii) multiple follow-on public offerings, raising over $450 million, (iv) a licensing transaction with Daiichi Sankyo Europe in which Esperion received $300 million in upfront and near-term milestones, up to $900 million in total milestones and substantial tiered royalties and (v) $200 million royalty-based funding agreement with an investor group led by Oberland Capital
  • AVROBIO, a Phase 2 clinical-stage gene therapy company, in its (i) seed financing with Atlas Ventures, (ii) $25 million and $60 million private financings, (iii) in-license transaction with University Health Network (UHN), (iv) $115 million initial public offering and (v) $115 million follow-on public offering
  • Akili Interactive Labs, a prescription digital medicine company, in its (i) $68 million Series C financing and (ii) strategic partnership with Shionogi & Co.
  • Rubius, a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, in its (i) $120 million Series B financing, (ii) $100 million Series C financing and (iii) $275 million initial public offering
  • Neon Therapeutics, a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, in its (i) $106 million crossover financing and (ii) $100 million initial public offering
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, in its $118 million initial public offering
  • Radius Health in its $300 convertible note financing
  • scPharma, a pharmaceutical company, in its (i) $45 million crossover financing and $95 million initial public offering
  • Qrativ in its formation as a joint venture among the Mayo Clinic, Nference and leading investors contributing more than $8 million in Series A financing
  • Agenus Inc., a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, in a $230 million royalty financing transaction with HealthCare Royalty Partners, $115 million royalty bond financing transaction with an investor group led by Oberland Capital and $15 million royalty transaction with XOMA Corporation, where XOMA purchased a minority interest in the royalties and milestones that Agenus is eligible to receive from Incyte and Merck
  • H.I.G. BioHealth Partners in its lead investor role in the $22.6 million private financing of Exagen Inc.
  • Guide Medical Ventures in its formation and financing of more than half a dozen portfolio companies
  • Leading investment banks in follow-on public offerings of Sarepta Therapeutics raising more than $700 million
  • JP Morgan and other leading investment banks in the $100 million initial public offering of InflaRx and $102 million follow-on offering
  • Jefferies and other leading investment banks in the $77 million initial public offering of AC Immune
  • Credit Suisse and other leading investment banks in the $85 million follow-on public offering of AC Immune
  • Alnylam Pharmaceuticals, the leading RNAi therapeutics company, in its transformational alliance for the development and commercialization of RNAi therapeutics with Genzyme, a Sanofi company, under which Genzyme purchased $700 million of Alnylam common equity and obtained a series of options to purchase regional (i.e., ex-North America and Western Europe), co-development or global licenses to various Alnylam product candidates
  • Nimbus Therapeutics in its (i) co-development collaboration with Shire plc which focused on of first-in-class small molecule treatments for several rare genetic diseases, (ii) co-development collaboration with Monsanto which focused on a broad-spectrum fungicides, (iii) private financings, including a $24 million Series A financing and $43 million Series B financing and (iv) sale of its Acetyl-CoA Carboxylase (ACC) inhibitor program to Gilead for $400 million upfront and the potential to receive an additional $800 million
  • Warp Drive Bio, astrategic partnership between Third Rock Ventures and Sanofi, in Warp Drive Bio’s initial $125 million financing and defined collaboration deal, the 2016 extension of this collaboration and Warp Drive’s acquisition by Revolution Medicines
  • SmartCells, Inc., a private biotechnology company developing a glucose responsive insulin, in its capital raising and ongoing operations as well as its ultimate sale to Merck & Co. for an upfront cash payment as well as potential clinical development and regulatory milestones in excess of $500 million and royalties
  • Yumanity Therapeutics, a company focused on discovering transformative therapies to treat neurodegenerative diseases, in its $45 million Series A financing
  • Underwriters and selling stockholders in other initial public and following equity offerings raising more than $2 billion
  • Intellect Medical, a private medical device company developing technologies for deep brain stimulation, in its sale to Boston Scientific in a transaction valued at $78 million
Professional Experience

Prior to joining Goodwin, Mr. McGivern was an associate in the Business Practice Group at Testa, Hurwitz & Thibeault in Boston.

Recognition

Mr. McGivern is recognized in the the 2020 edition of The Best Lawyers in America as a Biotechnology and Life Sciences Practice best lawyer and in the 2013 edition of The Legal 500 United States for his work in Healthcare: Life Sciences. Mr. McGivern is recognized as member of the Foundation Medicine deal team, which led Goodwin to be recognized by Financial Times (FT) as one of the most innovative law firms in its 2015 North America Innovative Lawyers report.

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 2004
Boston University School of Law

(cum laude)

B.S.C.E., 1997
Tufts University

(cum laude)

Admissions

Bar

Massachusetts
Get In Touch
Kontakt
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师